レムデシビルで治療された呼吸不全合併COVID-19 7 例において観察された臨床的効果と有害事象について

抄録

A preliminary report from a global study showed that remdesivir, a nucleoside analog pro-drug that was originally developed as a therapeutic drug against Ebola virus, may exert clinical efficacy in cases of COVID-19, by shortening the time to recovery. We had the opportunity to use this new drug in the treatment of 7 COVID-19 patients with respiratory failure.